Having earned his bachelor of business administration degree from Iona College in New Rochelle, New York, Richard DiVenuto launched a financial advisory career. More recently, Richard DiVenuto has served as an advisor to biotech firms headquartered in areas such as Florida, California, and Boston, Massachusetts, including companies that study how cells derived from the postpartum placenta may be used as treatment for various diseases, including cancer.
New treatments developed by researchers aim to use cells from the human placenta to treat conditions, such as infectious disease, degenerative disease, and cancer. The practice offers an alternative to the expensive method of autologous cell therapy, requiring the use of cells from the patient themselves. According to research, cells from a postpartum placenta typically do not trigger an immune response from a host, meaning that there is a lower risk of rejection.
A study published in 2019 observed how CAR T cells from a placenta fought off tumors and provided other benefits with fewer negative side effects in mice. Hosts experienced fewer instances of rejection after receiving the treatment as well.
New treatments developed by researchers aim to use cells from the human placenta to treat conditions, such as infectious disease, degenerative disease, and cancer. The practice offers an alternative to the expensive method of autologous cell therapy, requiring the use of cells from the patient themselves. According to research, cells from a postpartum placenta typically do not trigger an immune response from a host, meaning that there is a lower risk of rejection.
A study published in 2019 observed how CAR T cells from a placenta fought off tumors and provided other benefits with fewer negative side effects in mice. Hosts experienced fewer instances of rejection after receiving the treatment as well.
